Preclinical good laboratory practice-compliant safety study to evaluate biodistribution and tumorigenicity of a cartilage advanced therapy medicinal product (ATMP)

Abstract

BackgroundThe clinical development of advanced therapy medicinal products (ATMPs), a new class of drugs, requires initial safety studies that deviate from standard non-clinical safety protocols. The study provides a strategy to address the safety aspects of biodistribution and tumorigenicity of ATMPs under good laboratory practice (GLP) conditions avoiding cell product manipulation. Moreover, the strategy was applied on a human ATMP for cartilage repair.MethodsThe testing strategy addresses biodistribution and tumorigenicity using a multi-step analysis without any cell manipulation to exclude changes of test item characteristics. As a safeguard measurement for meeting regulatory expectations, the project design and goals were discussed continuously with the regulatory authority using a staggered scientific advice concept. Subsequently, the strategy was applied to co.don chondrosphere® (huChon spheroid), a tissue-engineered matrix-free ATMP of human normal chondrocytes. In both the biodistribution and tumorigenicity studies, huChon spheroids were implanted subcutaneously into 40 immunodeficient mice. Biodistribution was studied 1 month after implantation. A skin disc containing the huChon spheroid, two surrounding skin rings and selected organs were analyzed by validated, gender-specific, highly-sensitive triplex qPCR and by immunohistochemistry (IHC).ResultsNo human DNA was detected in distant skin rings and analyzed organs. IHC revealed no direct or indirect indications of cell migration. Tumorigenicity was assessed 6 months after huChon spheroid implantation by palpation, macroscopic inspection, histology and IHC. No mice from the huChon spheroid group developed a tumor at the implantation site. In two mice, benign tumors were detected that were negative for HLA-ABC, suggesting that they were of spontaneous murine origin.ConclusionsIn summary, the presented strategy using a multi-step analysis was confirmed to be suitable for safety studies of ATMPs.Electronic supplementary materialThe online version of this article (doi:10.1186/s12967-015-0517-x) contains supplementary material, which is available to authorized users.

In VitroAnalysis of Cartilage Regeneration Using a Collagen Type I Hydrogel (CaReS) in the Bovine Cartilage Punch Model

“…These results argue for an advantage of cell-loaded versus cell-free collagen implants, in agreement with earlier studies on cellseeded or cell-containing implants based on collagen or other cartilage replacement materials. [41][42][43][44] Alternatively, in vivo microfracturing of the subchondral bone plate below the cartilage implant can be used to favor cell immigration into initially cell-free implants and optimize the conditions for successful cartilage repair. 39,40,45 Cell-free and cell-loaded collagen implants both showed progressive deposition of the matrix molecule aggrecan and a stable protein content of collagen 2 throughout culture, again demonstrating the cytocompatibility of the implant material and the active production of cartilage-specific matrix molecules by vital chondrocytes.…”

Preclinical Studies of the Biosafety and Efficacy of Human Bone Marrow Mesenchymal Stem Cells Pre-Seeded into β-TCP Scaffolds after Transplantation

“…In contrast, subcutaneous implantation is an easy and non-invasive technique, and allows performance of several test items in the same animal [27]. …”

Concepts in regenerative medicine: Past, present, and future in articular cartilage treatment

“…[23][24][25][26][27][28] Although the rules and regulations remain unclear, clinicians that are interested should carry-on with the best available guidelines to ensure safety and compliance during delivery in clinical practice to avoid regulatory infraction. 29 While ill-defined regulation encourages experimentation and novel clinical application, efficacy and patient safety concerns are a real concern.…”